首页>投融资

Alto Neuroscience

上市

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing first-in-class precision medicines, using its proprietary artificial intelligence (AI)-based brain biomarker platform, for the potential treatment of psychiatry disorders, including depression, post-traumatic stress disorder (PTSD), and other mental health diseases.In January 2023, the company announced it closed a USD 25 million equity investment with new investor Alpha Wave Ventures, ringing its total Series B funding to USD 60 million and total equity capital raised to USD 100 million. The company also entered into a credit facility for up to USD 35 million with K2 HealthVentures,.In October 2022, the company closed a USD 35 million Series B financing

https://www.altoneuroscience.com/

470211

基本信息

公司全称

Alto Neuroscience Inc
类型

心理健康治疗药物研发商
产业领域

医药研发/制造、化学&生物药
公司人数

51~100人
地址

369 South San Antonio Road Los Altos California 94022; US;
联系电话

1-650-2000412
邮箱

info@altoneuroscience.com
成立时间

2019-01-01

投融资

2024-02-02

上市

1.20亿美元

未透露
2023-11-21

C轮

4500万美元

InVivium Capital

Franklin Templeton Investments

Point 72

Eli Lilly

Alpha Wave

What If Ventures

Alkeon Capital Management

Alexandria Venture Investments

Lightswitch Capital

Windham Venture Partners
2023-01-30

B轮

2500万美元

Alpha Wave
2022-10-25

B轮

3500万美元

Alkeon Capital Management

Lightswitch Capital

Windham Venture Partners

What If Ventures

Gaingels

Vine Ventures

Korify Capital

Valor Equity Partners

诺华

Sobrato Capital
2021-10-15

A轮

3200万美元

Windham Venture Partners

Able Partners

What If Ventures

Apeiron Investment Group
加载更多

Alto Neuroscience

基本信息

投融资

相关投融资企业